Regeneron Pharmaceuticals Inc

American biotechnology company headquartered at Tarrytown in New York, founded in 1988 by Leonard Schleifer and George Yancopoulos and listed on Nasdaq. Discovers, develops and manufactures medicines using its VelocImmune and VelociSuite antibody and genetics platforms, with marketed products including aflibercept for eye disease, dupilumab for atopic and inflammatory disease developed with Sanofi, cemiplimab in oncology and antibody treatments for infectious disease, and operates the Regeneron Genetics Center and manufacturing plants in New York and Ireland.